[A20-07] Trastuzumab emtansine (breast cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 15.04.2020
Project no.:
A20-07
Commission:
Commission awarded on 14.01.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with HER2-positive early breast cancer who have residual disease, in the breast and/or lymph nodes, after preoperative systemic treatment including anti-HER2 treatment
Negative effects in morbidity, health-related quality of life and side effects do not completely call into question the positive effect in recurrence; indication of minor added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A14-01 | Trastuzumab emtansine - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |